Relationship between the serum uric acid level, visceral fat accumulation and serum adiponectin concentration in Japanese men.

OBJECTIVE Visceral fat accumulation is an underlying component of the metabolic syndrome (MetS). Hypoadiponectinemia is one of the key molecules of the MetS. In the present study, we investigated the relationship between the serum uric acid level, visceral fat accumulation and serum adiponectin concentration in Japanese men. PATIENTS AND METHODS The study group comprised 1,520 Japanese employed men (mean age: 45.6+/-10.4 years, +/- SD), who had undergone an annual health check-up both in 2004 and 2005. In addition to parameters measured in the annual health check-up, visceral fat area (VFA) and serum adiponectin concentration were measured by the bioelectrical impedance analysis method and a sandwich enzyme-linked immunosorbent assay (ELISA) system, respectively. RESULTS Visceral fat accumulation was identified in 56.1% of the subjects with hyperuricemia. There was significant positive correlation between visceral fat area and serum uric acid levels (r=0.223, p<0.0001), and negative correlation between serum adiponectin concentration and serum uric acid levels (r=-0.198, p<0.0001). The one-year change in VFA was associated with the one-year change in serum uric acid levels. Stepwise multiple regression analysis showed that VFA and the serum adiponectin concentration were significant explanatory variables for serum uric acid levels. CONCLUSION Hyperuricemia is significantly associated with visceral fat accumulation and hypoadiponectinemia in Japanese men.

[1]  岡内 幸義.  Reduction of Visceral Fat Is Associated With Decrease in the Number of Metabolic Risk Factors in Japanese Men , 2008 .

[2]  W. Rathmann,et al.  Ten-year change in serum uric acid and its relation to changes in other metabolic risk factors in young black and white adults: the CARDIA study , 2007, European Journal of Epidemiology.

[3]  D. Tsai,et al.  Association Between Serum Uric Acid Level and Components of the Metabolic Syndrome , 2006, Journal of the Chinese Medical Association : JCMA.

[4]  A. Onat,et al.  Serum uric acid is a determinant of metabolic syndrome in a population-based study. , 2006, American journal of hypertension.

[5]  Y. Matsuzawa.  The metabolic syndrome and adipocytokines , 2006, FEBS letters.

[6]  In-kyu Lee,et al.  Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. , 2005, Journal of the American Society of Nephrology : JASN.

[7]  Byung Jin Kim,et al.  Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. , 2005, Circulation journal : official journal of the Japanese Circulation Society.

[8]  Makoto Nishida,et al.  A new simple method for the measurement of visceral fat accumulation by bioelectrical impedance. , 2005, Diabetes care.

[9]  S. Kihara,et al.  Adiponectin as a biomarker of the metabolic syndrome. , 2004, Circulation journal : official journal of the Japanese Circulation Society.

[10]  M. Elisaf,et al.  Alcohol intake, serum uric acid concentrations, and risk of gout , 2004, The Lancet.

[11]  Nader Rifai,et al.  Plasma adiponectin levels and risk of myocardial infarction in men. , 2004, JAMA.

[12]  Elizabeth W Karlson,et al.  Purine-rich foods, dairy and protein intake, and the risk of gout in men. , 2004, The New England journal of medicine.

[13]  S. Grundy,et al.  The metabolic syndrome , 2003, The Lancet.

[14]  K. Tuttle,et al.  Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? , 2003, Hypertension.

[15]  Helen Santini.  Rebirth of the health-care system in Cambodia , 2002, The Lancet.

[16]  S. Kihara,et al.  Adiponectin Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice , 2002, Circulation.

[17]  Jonathan Krakoff,et al.  Adiponectin and development of type 2 diabetes in the Pima Indian population , 2002, The Lancet.

[18]  M. Matsuda,et al.  Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 , 2002, Nature Medicine.

[19]  L. Groop,et al.  Cardiovascular morbidity and mortality associated with the metabolic syndrome. , 2001, Diabetes care.

[20]  F Santeusanio,et al.  Relation Between Serum Uric Acid and Risk of Cardiovascular Disease in Essential Hypertension: The PIUMA Study , 2000, Hypertension.

[21]  Jing Fang,et al.  Serum Uric Acid and Cardiovascular Mortality: The NHANES I Epidemiologic Follow-up Study, 1971-1992 , 2000 .

[22]  Daniel Levy,et al.  Serum Uric Acid and Risk for Cardiovascular Disease and Death: The Framingham Heart Study , 1999, Annals of Internal Medicine.

[23]  T Nakamura,et al.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. , 1999, Biochemical and biophysical research communications.

[24]  H. Ward.  Uric acid as an independent risk factor in the treatment of hypertension , 1998, The Lancet.

[25]  J. Seidell,et al.  Impairment of health and quality of life in people with large waist circumference , 1998, The Lancet.

[26]  R. Switzer,et al.  The genetic and functional basis of purine nucleotide feedback-resistant phosphoribosylpyrophosphate synthetase superactivity. , 1995, The Journal of clinical investigation.

[27]  T Nakamura,et al.  Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. , 1994, Atherosclerosis.

[28]  G. Reaven,et al.  Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. , 1991, JAMA.

[29]  I. Fabregat,et al.  Short-term control of the pentose phosphate cycle by insulin could be modulated by the NADPH/NADP ratio in rat adipocytes and hepatocytes. , 1987, Biochemical and biophysical research communications.

[30]  A. Kissebah,et al.  Relation of Body Fat Distribution to Metabolic Complications of Obesity , 1982 .

[31]  I. Fox,et al.  Metabolic basis for disorders of purine nucleotide degradation. , 1981, Metabolism: clinical and experimental.

[32]  J. Sutton,et al.  Purine metabolism during strenuous muscular exercise in man. , 1976, Metabolism: clinical and experimental.

[33]  J. S. Sutherland,et al.  Plasma uric acid concentrations among Edinburgh business executives. , 1969, JAMA.

[34]  J. Overall,et al.  Relationship of obesity to serum triglyceride, cholesterol, and uric acid, and to plasma-glucose levels. , 1967, The American journal of clinical nutrition.

[35]  V. Křížek.  Serum Uric Acid in Relation to Body Weight , 1966, Annals of the rheumatic diseases.

[36]  T. Hosoya,et al.  Relationship between hyperuricemia and body fat distribution. , 2007, Internal medicine.

[37]  L. Bielak,et al.  Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis. , 2007, American journal of hypertension.

[38]  Yuichiro Oka,et al.  Relationship between serum uric acid concentration, metabolic syndrome and carotid atherosclerosis. , 2006, Internal medicine.

[39]  T. Funahashi,et al.  Decreased plasma adiponectin concentration in patients with essential hypertension. , 2003, American journal of hypertension.

[40]  Y. Matsuzawa,et al.  A novel technique for the determination of body fat by computed tomography. , 1983, International journal of obesity.